Catalent Pharma Solutions wins FDA approval for gastric drug

Catalent Pharma Solutions, a developer of drug delivery technology, has reported that the FDA has granted marketing approval for Metozolv ODT metoclopramide HCL utilizing the company's Zydis fast dissolve technology.

Metozolv orally disintegrating tablets (ODT) was developed by Wilmington Pharmaceuticals and licensed to Salix Pharmaceuticals.

Metozolv ODT is reportedly the first orally disintegrating tablet formulation for both acute and recurrent diabetic gastroparesis and for the treatment of short-term therapy for adults with symptomatic documented gastroesophageal reflux disease who fail to respond to conventional therapy.

Ian Muir, vice president and general manager of modified release technologies business at Catalent, said: "The launch of Metozolv ODT exclusively in a Zydis fast dissolve tablet once again demonstrates its ability to deliver unique patient benefits, and we are pleased to collaborate with Wilmington and Salix on this exciting launch."

http://www.datamonitor.com
Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall 
not be liable for errors or delays in the content, or for any actions 
taken in reliance thereon

Related terms: business, disease, fda, marketing, pharmaceuticals, president, technology